Anti-TGF-<i>ß</i>1 Antibody Therapy in Patients with Diabetic Nephropathy.
Voelker, James; Berg, Paul H; Sheetz, Matthew; Duffin, Kevin; Shen, Tong; Moser, Brian; Greene, Tom; Blumenthal, Samuel S; Rychlik, Ivan; Yagil, Yoram; Zaoui, Philippe; Lewis, Julia B.
J Am Soc Nephrol
; 28(3): 953-962, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-27647855
Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy.
Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy.
TGF-ß: the connecting link between nephropathy and fibrosis.
[Molecular regulative mechanisms of NLRP3 inflammasome activation in diabetic nephropathy and interventional effects of Chinese herbal medicine].
SGLT2 inhibition to address the unmet needs in diabetic nephropathy.
Podocytes: Way to Go.
CXCL16 deficiency attenuates diabetic nephropathy through decreasing oxidative stress and inflammation.
Pentoxifylline for diabetic kidney disease.
[Efficacy and safety of Buyang Huanwu Decoction for early-stage diabetic nephropathy: a Meta-analysis].
[Effect of Shenqi Dihuang decoction on inflammatory factor, renal function and microcirculation in patients with early diabetic nephropathy].